Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HMPL-306 versus salvage chemotherapy for relapsed/refractory IDH1- or IDH2-mutant acute myeloid leukemia
CTR20240999Phase 3Active
- Sponsor
- HUTCHMED
- Start
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ranosidenib in acute myeloid leukemia (AML), sponsored by HUTCHMED. Started May 2024; status: active.
02
Drugs
ranosidenib
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on CTR20240999.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20240999.